CO5190714A1 - PHOSPHATE TRANSPORTATION INHIBITORS - Google Patents
PHOSPHATE TRANSPORTATION INHIBITORSInfo
- Publication number
- CO5190714A1 CO5190714A1 CO00053928A CO00053928A CO5190714A1 CO 5190714 A1 CO5190714 A1 CO 5190714A1 CO 00053928 A CO00053928 A CO 00053928A CO 00053928 A CO00053928 A CO 00053928A CO 5190714 A1 CO5190714 A1 CO 5190714A1
- Authority
- CO
- Colombia
- Prior art keywords
- ammonium
- sulfonyl
- group
- sulphonyl
- alkylsulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
Abstract
Un método para inhibir el transporte de fosfato dependiente del sodio, por medio de administrar a un sujeto que lo necesite, una cantidad segura y efectiva de un compuesto de acuerdo con la fórmula (I):<EMI FILE="00053928_1" ID="1" IMF=JPEG >donde:R1 y R2 se seleccionan independientemente del grupo constituido por hidrógeno, alquilo, alquenilo, arilalquilo, acilo, aroilo, haloalquilo, halo, carboxi, carboalcoxi, carbamoilo, alquilcarbamoilo, arilcarbamoilo, ciano, alcoxi, hidroxilo, fenilazo, amino, nitro, alquilamino, arilamino, arilalquilamino, acilamino, aroilamino, alquiltio, arilalquiltio, ariltio, alquisulfinilo, arilsulfinilo, arilalquilsulfinilo, alquilsulfonilo, arilsulfonilo, arilalquilsulfonilo, sulfamoilo, arilsulfonamido, y alquilsulfonamido;o el resto R1 representa un anillo condensado que forma un benzotiofeno, naftaleno, quinolina, o isoquinolina con el anillo del que es sustituyente;o (R1)n y el anillo del que es sustituyente, representa un heterociclo seleccionado del grupo constituido por tiofeno, furano, piridina, pirimidina, y pirazina, y sus benzo-análogos; yR3 se selecciona independientemente del grupo constituido por alquilo, haloalquilo, R1-arilo y R1-aralquilo, y heterociclos sustituidos con R1 seleccionados del grupo constituido por tionfeno, furano, piridina, pirimidina, pirazina, imidazol, y tiazol, y sus benzo-análogos. Un método para producir la excreción de fosfato y/o para inhibir la absorción de fosfato, por medio de administrar a un sujeto que lo necesite, una cantidad segura y efectiva de un compuesto de acuerdo con la fórmula (I):<EMI FILE="00053928_2" ID="2" IMF=JPEG >donde:R1 y R2 se seleccionan independientemente del grupo constituido por hidrógeno, alquilo, alquenilo, arilalquilo, acilo, aroilo, haloalquilo, halo, carboxi, carboalcoxi, carbamoilo, alquilcarbamoilo, arilcarbamoilo, ciano, alcoxi, hidroxilo, fenilazo, amino, nitro, alquilamino, arilamino, arilalquilamino, acilamino, aroilamino, alquiltio, arilalquiltio, ariltio, alquisulfinilo, arilsulfinilo, arilalquilsulfinilo, alquilsulfonilo, arilsulfonilo, arilalquilsulfonilo, sulfamoilo, arilsulfonamido, y alquilsulfonamido; ...A method to inhibit sodium dependent phosphate transport, by administering to a subject in need, a safe and effective amount of a compound according to formula (I): <EMI FILE = "00053928_1" ID = " 1 "MFI = JPEG> where: R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, acyl, aroyl, haloalkyl, halo, carboxy, carboalkoxy, carbamoyl, alkylcarbamoyl, arylcarbamoyl, cyano, alkoxy, hydroxyl, phenylazo, amino, nitro, alkylamino, arylamino, arylalkylamino, acylamino, aroylamino, alkylthio, arylalkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylalkylsulfinyl, alkylsulfonyl, arylsulfonyl, arylalkyl sulfonyl, sulfamoyl, sulfonamide, arylsulfonamide forms a benzothiophene, naphthalene, quinoline, or isoquinoline with the ring of which it is a substituent; or (R1) n and the ring of which it is a substituent, represents a selected heterocycle from the group consisting of thiophene, furan, pyridine, pyrimidine, and pyrazine, and their benzo-analogs; and R3 is independently selected from the group consisting of alkyl, haloalkyl, R1-aryl and R1-aralkyl, and R1 substituted heterocycles selected from the group consisting of thionphene, furan, pyridine, pyrimidine, pyrazine, imidazole, and thiazole, and their benzo-analogs . A method for producing phosphate excretion and / or for inhibiting phosphate absorption, by administering to a subject in need, a safe and effective amount of a compound according to formula (I): <EMI FILE = "00053928_2" ID = "2" MFI = JPEG> where: R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, acyl, aroyl, haloalkyl, halo, carboxy, carboalkoxy, carbamoyl, alkylcarbamoyl, arylcarbamoyl, cyano, alkoxy, hydroxy, phenylazo, amino, nitro, alkylamino, arylamino, arylalkylamino, acylamino, aroylamino, alkylthio, arylalkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylalkylsulfinyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, alkylsulfonyl, alkylsulfonyl ammonium ammonium ammonium sulfonammonium ammonium sulfonyl ammonium ammonium alkyl ammonium sulfonyl ammonium ammonium sulfonamylsulfonyl ammonium ammonium sulfonyl ammonium ammonium sulphonyl ammonium ammonium sulphonyl ammonium ammonium sulfonyl ammonium ammonium sulphonyl ammonium sulphonyl ammonium sulphonyl ammonium ammonium compounds ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14464699P | 1999-07-20 | 1999-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5190714A1 true CO5190714A1 (en) | 2002-08-29 |
Family
ID=22509500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00053928A CO5190714A1 (en) | 1999-07-20 | 2000-07-18 | PHOSPHATE TRANSPORTATION INHIBITORS |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1202729A1 (en) |
JP (1) | JP2003504403A (en) |
KR (1) | KR20020015382A (en) |
CN (1) | CN1361687A (en) |
AR (1) | AR030911A1 (en) |
AU (1) | AU6354300A (en) |
BR (1) | BR0012568A (en) |
CA (1) | CA2379657A1 (en) |
CO (1) | CO5190714A1 (en) |
CZ (1) | CZ2002204A3 (en) |
HU (1) | HUP0202938A3 (en) |
IL (1) | IL147697A0 (en) |
MX (1) | MXPA02000753A (en) |
NO (1) | NO20020278D0 (en) |
NZ (1) | NZ516619A (en) |
PL (1) | PL353741A1 (en) |
TR (1) | TR200200112T2 (en) |
WO (1) | WO2001005398A1 (en) |
ZA (1) | ZA200200464B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2408667A1 (en) * | 2000-05-12 | 2001-11-22 | Joseph Weinstock | Phosphate transport inhibitors |
GB2378179A (en) * | 2001-08-03 | 2003-02-05 | Pantherix Ltd | Aromatic sulfonamides and their use in treating bacterial diseases |
AUPR738301A0 (en) * | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
US7119120B2 (en) * | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
US7582673B2 (en) | 2004-10-21 | 2009-09-01 | High Point Pharmaceuticals, Llc | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use |
WO2006077901A1 (en) * | 2005-01-20 | 2006-07-27 | Shionogi & Co., Ltd. | Ctgf expression inhibitor |
EP2307019A1 (en) * | 2008-06-03 | 2011-04-13 | Fresenius Medical Care Deutschland GmbH | Pharmaceutical compositions comprising gamma secretase modulators |
KR20200111230A (en) | 2008-12-31 | 2020-09-28 | 알데릭스, 인코포레이티드 | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US8664425B2 (en) | 2010-02-02 | 2014-03-04 | Honeywell International Inc. | Bluegreen fluorescent compounds |
JP5827328B2 (en) | 2010-07-07 | 2015-12-02 | アーデリクス,インコーポレーテッド | Compounds and methods for inhibiting phosphate transport |
EP2590655B1 (en) * | 2010-07-07 | 2015-06-24 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
JP5827327B2 (en) * | 2010-07-07 | 2015-12-02 | アーデリクス,インコーポレーテッド | Compounds and methods for inhibiting phosphate transport |
JP5823514B2 (en) * | 2010-07-07 | 2015-11-25 | アーデリクス,インコーポレーテッド | Compounds and methods for inhibiting phosphate transport |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
WO2014029983A1 (en) | 2012-08-21 | 2014-02-27 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
CN103183623A (en) * | 2013-03-12 | 2013-07-03 | 中国医学科学院医药生物技术研究所 | A group of benzene sulfonamido benzamide derivatives, and preparation and application thereof |
MX2015014351A (en) | 2013-04-12 | 2016-04-20 | Ardelyx Inc | Nhe3-binding compounds and methods for inhibiting phosphate transport. |
CN105395532B (en) * | 2015-11-25 | 2017-11-14 | 中国医学科学院医药生物技术研究所 | Application of the 2 benzene sulfonamido benzamide compounds in liver injury protection and liver fibrosis preventing and treating |
EP3508475A4 (en) | 2016-08-30 | 2020-04-15 | Nippon Soda Co., Ltd. | Sulfonylamino benzamide compound and pest control agent |
AU2018205400B2 (en) | 2017-01-09 | 2022-07-14 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
CN110291082A (en) | 2017-01-09 | 2019-09-27 | 阿德利克斯股份有限公司 | The inhibitor for the antiport that NHE is mediated |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL86462A (en) * | 1987-05-29 | 1992-12-01 | Fujisawa Pharmaceutical Co | Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same |
US5210079A (en) * | 1988-01-07 | 1993-05-11 | E. I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists |
-
2000
- 2000-07-18 AR ARP000103686A patent/AR030911A1/en not_active Application Discontinuation
- 2000-07-18 CO CO00053928A patent/CO5190714A1/en not_active Application Discontinuation
- 2000-07-19 CA CA002379657A patent/CA2379657A1/en not_active Abandoned
- 2000-07-19 CN CN00810644A patent/CN1361687A/en active Pending
- 2000-07-19 NZ NZ516619A patent/NZ516619A/en unknown
- 2000-07-19 HU HU0202938A patent/HUP0202938A3/en unknown
- 2000-07-19 TR TR2002/00112T patent/TR200200112T2/en unknown
- 2000-07-19 WO PCT/US2000/019616 patent/WO2001005398A1/en active IP Right Grant
- 2000-07-19 JP JP2001510455A patent/JP2003504403A/en not_active Withdrawn
- 2000-07-19 BR BR0012568-7A patent/BR0012568A/en not_active Application Discontinuation
- 2000-07-19 CZ CZ2002204A patent/CZ2002204A3/en unknown
- 2000-07-19 PL PL00353741A patent/PL353741A1/en not_active Application Discontinuation
- 2000-07-19 KR KR1020027000801A patent/KR20020015382A/en not_active Application Discontinuation
- 2000-07-19 MX MXPA02000753A patent/MXPA02000753A/en unknown
- 2000-07-19 AU AU63543/00A patent/AU6354300A/en not_active Abandoned
- 2000-07-19 IL IL14769700A patent/IL147697A0/en unknown
- 2000-07-19 EP EP00950437A patent/EP1202729A1/en not_active Withdrawn
-
2002
- 2002-01-18 NO NO20020278A patent/NO20020278D0/en not_active Application Discontinuation
- 2002-01-18 ZA ZA200200464A patent/ZA200200464B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL353741A1 (en) | 2003-12-01 |
MXPA02000753A (en) | 2002-07-22 |
NO20020278L (en) | 2002-01-18 |
HUP0202938A2 (en) | 2003-01-28 |
WO2001005398A1 (en) | 2001-01-25 |
AR030911A1 (en) | 2003-09-03 |
IL147697A0 (en) | 2002-08-14 |
EP1202729A1 (en) | 2002-05-08 |
NO20020278D0 (en) | 2002-01-18 |
CZ2002204A3 (en) | 2002-11-13 |
KR20020015382A (en) | 2002-02-27 |
CN1361687A (en) | 2002-07-31 |
HUP0202938A3 (en) | 2006-07-28 |
CA2379657A1 (en) | 2001-01-25 |
ZA200200464B (en) | 2003-04-30 |
TR200200112T2 (en) | 2002-05-21 |
AU6354300A (en) | 2001-02-05 |
JP2003504403A (en) | 2003-02-04 |
NZ516619A (en) | 2004-02-27 |
BR0012568A (en) | 2002-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5190714A1 (en) | PHOSPHATE TRANSPORTATION INHIBITORS | |
AR043038A1 (en) | PIRAZOLOTRIAZINE COMPOUNDS AND USES OF THE SAME | |
TR200101893T2 (en) | 4-oxo-1,4 dihydro -3-quinolinecarboxamides as antiviral agents. | |
CO5460265A1 (en) | CHEMICAL COMPOUNDS | |
PE20001484A1 (en) | DERIVATIVES OF NAFTALEN-1-ILO UREA AND CARBAMIC ACID | |
PE20030200A1 (en) | BENZHIMIDAZOLE AS INHIBITORS OF MAP KINASES | |
ES544349A0 (en) | A PROCEDURE FOR THE PREPARATION OF BENZOFURAN DERIVATIVES. | |
DE3373306D1 (en) | Succinimide derivatives and their production | |
AR019365A1 (en) | COMPOSITE OF 1-PIPERIDIN-3-PHENYL-BUTIL-NAFTAMIDE, PROCESS TO PREPARE IT, PHARMACEUTICAL COMPOSITION AND USE TO MANUFACTURE A USEFUL MEDICINAL PRODUCT FOR THE PROCESSING OF A DISEASE BY ENDOGENIC NEUROPEPTIDIC TACHYCINES | |
HU9301084D0 (en) | (1,2,4-oxadozolyl-phenoxi-alkyl)-isoxazole derivatives and their application as anti-viral agent | |
EP1176958A4 (en) | Novel catechols as antimicrobial agents | |
WO1999062909A3 (en) | Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents | |
DE60014404D1 (en) | AMINOBENZOPHENONE AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | |
KR850008489A (en) | Preparation of Cephalosporin Derivatives | |
PT80779B (en) | PROCESS FOR THE PREPARATION OF NOVEL 2-AMINO-OXAZOLINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
EP0994113A3 (en) | 7-Aminopyrido(2,3-d)-pyrimidine derivatives for treatment of bronchial asthma | |
RS50109B (en) | 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists | |
KR880009021A (en) | Pyrazolo [3,4-d] pyrimidine derivatives, compositions and uses thereof | |
EP1144393A3 (en) | Heterocyclic derivatives and their use as integrin inhibitor | |
WO2000018741A3 (en) | Pyrazole compounds as cox-2 inhibitors | |
ES8302006A1 (en) | Cephalosporins, process for their preparation and pharmaceutical compositions containing them. | |
DE69838385D1 (en) | ANGIOGENESIS-INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES | |
ES8305369A1 (en) | Cephalosporins, process for their preparation and pharmaceutical compositions containing them. | |
ATE49601T1 (en) | NEW 11-PIPERAZINYL-5H-IMIDAZO(2,1C>(1,4>BENZODIAZEPINS, PROCESSES FOR THEIR PREPARATION AND INTERMEDIATE PRODUCTS AND PHARMACEUTICALS CONTAINING THE FIRST. | |
KR910007901A (en) | 5- {2-[(2-amino-2-oxoethyl) (methyl) amino] ethyl} -2,3-dihydro-3-hydroxy-2- (4-methoxyphenyl) -1,5 ( 5H) -benzothiazepin-4-one derivatives. Its use in its manufacture and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |